News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
31 October 2023
Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
29 September 2023
Invitation to investor meeting 3rd October 2023, 2:00 pm (CET)
20 September 2023
Molecure submits application to the European Medicines Agency (EMA) to initiate a phase II clinical trial in the European Union and Norway to investigate OATD-01 for the treatment of pulmonary sarcoidosis
9 September 2023
The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
22 July 2023
Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies
19 July 2023